Affordable Access

Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival.

Authors
  • Schiller, J H
  • Storer, B
  • Berlin, J
  • Wittenkeller, J
  • Larson, M
  • Pharo, L
  • Larson, M
  • Berry, W
Type
Published Article
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publication Date
Jun 01, 1996
Volume
14
Issue
6
Pages
1913–1921
Identifiers
PMID: 8656260
Source
Medline
License
Unknown

Abstract

ACV appears to be a highly active regimen in metastatic NSCLC. Acute toxicities were generally reversible and the data suggest that amifostine may protect against long-term renal insufficiency from cumulative doses of cisplatin. Although the sample size of this trial is small, the results are significantly encouraging to warrant confirmation in randomized multiinstitutional trials.

Report this publication

Statistics

Seen <100 times